Global Active Pharmaceutical Ingredient (API) Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

November 2017 | 198 pages | ID: GBE693ED1D3EN
Precision Business Insights (PBI)

Abstracts

Global Active Pharmaceutical Ingredient (API) Market

Active pharmaceutical ingredient (API) Market is a part of the drug that produces a pharmacological effect. Some drugs such as combination therapy have multiple active pharmaceutical ingredients (API) to treat different symptoms in different ways. API’s provide health benefits and play a vital role in prevention, treatment and diagnosis. Active Pharmaceutical ingredients may synthesize by a chemical process, biotechnological process, and various other processes. Active pharmaceutical ingredients used for making the wide range of drugs that used to treat chronic diseases such as cancer, metabolic disorders, cardiovascular disorders, and neurological disorders, and others. Some market players manufacture their own API and others buy from other API manufacturing companies to make drug formulations.

Active pharmaceutical ingredient (API) market is driven by various factors such as the increase in the incidence of chronic diseases, and penetration of healthcare systems in underdeveloped countries increased the consumption of drugs are expected to fuel the growth of API market. Furthermore, a surge in healthcare spending, development of healthcare infrastructure around the world enables boost the growth of active pharmaceutical ingredients market. However, unfavourable drug pricing policies in some countries and stringent regulatory requirements are hampering the Active Pharmaceutical Ingredient Market

API market has been segmented based on the type of synthesis, and application area

Based on type of synthesis, Active Pharmaceutical Ingredient Market is segmented into

• Biotechnological
• Synthetic
• Semi-Synthetic

Based on application area, Active Pharmaceutical Ingredient Market is segmented into

• Cardiovascular system
• Oncology
• CNS & Neurological system
• Orthopaedic
• Endocrinology
• Pulmonology
• Gastrointestinal system
• Nephrology system
• Ophthalmology
• Others

Active Pharmaceutical Ingredient Market is witnessing robust growth rate over the forecast period. Globally API market is highly fragmented with many players. Market players are banking on mergers and acquisitions to expand their manufacturing capabilities, geographical expansions and to increase the market share. In September 2015, Sun Pharmaceuticals acquired GlaxoSmithKline’s (GSK’s) opiates business in Australia, to strengthen its active pharmaceutical ingredients (API) and analgesic drug segments. In July 2014, Hospira acquired API manufacturing facility and an associated R&D facility from Orchid Chemicals & Pharmaceuticals, an Indian pharmaceuticals company. This acquisition enables Hospira to vertically integrate into the beta-lactam antibiotic APIs. Furthermore, contract API manufacturing is growing at a significant rate owing to the low cost of manufacturing. New treatments for various diseases are expected to spur the demand for active pharmaceutical ingredients (API) across the globe.

Geographically API market segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America accounts major pie in API market over the forecast period. In addition, a rise in biotechnological advances led to rising demand for the active pharmaceutical ingredients in North America region. Asia-Pacific is expected to record the fastest CAGR owing to many manufacturers and favourable government policies in the region. Europe API market is expected to grow at a significant rate during the forecast period owing to manufacturers prioritizing high-quality standards, advanced manufacturing installations, and high purity of intermediates. In Europe, Russia is expected to grow with significant CAGR in the API manufacturing market owing to recent entry of many multinational companies and change in government policies are encouraging manufacturers to enter into the market.

Some of the players in API market are Pfizer, Inc. (U.S.), Sanofi (France), Lonza Group (Switzerland), Boehringer Ingelheim (Germany), Novartis AG (Switzerland), GlaxoSmithKline plc (U.K.), Bristol-Myers Squibb (U.S.), Zhejiang Hisun Pharmaceutical Co., Ltd. (China), Aenova Group GmbH (Germany), Catalent, Inc. (U.S.), Teva Pharmaceutical Industries Ltd., (Israel) Aurobindo Pharma Limited (India), Eli Lilly and Company (U.S.), AbbVie Inc. (U.S.)., and Merck & Co., Inc. (U.S.) to name a few.

In June 2017, Bristol-Myers Squibb Company signed a definitive purchase agreement to divest its small-molecule active pharmaceutical ingredient (API) production facility in Ireland, to South Korean firm SK BIOTEK CO. LTD.

In November 2014, US-based AbbVie has acquired a small molecule active pharmaceutical ingredient (API) manufacturing site in Tuas Biomedical Park, Singapore, to expand global operations of small molecule and biologics manufacturing.

Report Outline:

• The report provides granular level information about the market size, regional market share and forecast from 2017-2023
• The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
• The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
• The report tracks recent innovations, key developments and startup’s details that are working in the industry
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET INTRODUCTION

2.1. Global Active Pharmaceutical Ingredients Market – Taxonomy
2.2. Global Active Pharmaceutical Ingredients Market –Definitions
  2.2.1. Type of Synthesis
  2.2.2. Application

3. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Active Pharmaceutical Ingredients Market Dynamics – Factors Impact Analysis
3.6. Global Active Pharmaceutical Ingredients Market – Regulations
  3.6.1. U.S
  3.6.2. Europe
  3.6.3. Japan
  3.6.4. China
3.7. Global Active Pharmaceutical Ingredients Market – Product Innovations

4. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Biotechnological
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.1.3. Market Opportunity Analysis
5.2. Synthetic
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.2.3. Market Opportunity Analysis
5.3. Semi-Synthetic
  5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.3.3. Market Opportunity Analysis

6. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FORECAST, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Cardiovascular System
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.1.3. Market Opportunity Analysis
6.2. Oncology
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.2.3. Market Opportunity Analysis
6.3. CNS & Neurological System
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.3.3. Market Opportunity Analysis
6.4. Orthopaedic
  6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.4.3. Market Opportunity Analysis
6.5. Endocrinology
  6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.5.3. Market Opportunity Analysis
6.6. Pulmonology
  6.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.6.3. Market Opportunity Analysis
6.7. Gastrointestinal system
  6.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.7.3. Market Opportunity Analysis
6.8. Nephrology system
  6.8.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.8.3. Market Opportunity Analysis
6.9. Ophthalmology
  6.9.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.9.3. Market Opportunity Analysis
6.10. Others
  6.10.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.10.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.10.3. Market Opportunity Analysis

7. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. North America
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.1.3. Market Opportunity Analysis
7.2. Europe
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.3.3. Market Opportunity Analysis
7.4. Latin America
  7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
  7.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.5.3. Market Opportunity Analysis
7.6. Global Active Pharmaceutical Ingredients Market - Opportunity Analysis Index, By Type of Synthesis, Application and Region, 2017 – 2023

8. NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. Type of Synthesis Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  8.1.1. Biotechnological
  8.1.2. Synthetic
  8.1.3. Semi-Synthetic
8.2. Application Area Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  8.2.1. Cardiovascular system
  8.2.2. Oncology
  8.2.3. CNS & Neurological system
  8.2.4. Orthopaedic
  8.2.5. Endocrinology
  8.2.6. Pulmonology
  8.2.7. Gastrointestinal system
  8.2.8. Nephrology system
  8.2.9. Ophthalmology
  8.2.10. Others
8.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  8.3.1. U.S.
  8.3.2. Canada
8.4. North America Active Pharmaceutical Ingredients Market - Opportunity Analysis Index, By Type of synthesis, Application and Country, 2017 – 2023
8.5. North America Active Pharmaceutical Ingredients Market Dynamics – Trends

9. EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. Type of Synthesis Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  9.1.1. Biotechnological
  9.1.2. Synthetic
  9.1.3. Semi-Synthetic
9.2. Application Area Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  9.2.1. Cardiovascular system
  9.2.2. Oncology
  9.2.3. CNS & Neurological system
  9.2.4. Orthopaedic
  9.2.5. Endocrinology
  9.2.6. Pulmonology
  9.2.7. Gastrointestinal system
  9.2.8. Nephrology system
  9.2.9. Ophthalmology
  9.2.10. Others
9.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  9.3.1. Germany
  9.3.2. UK
  9.3.3. France
  9.3.4. Spain
  9.3.5. Italy
  9.3.6. Russia
  9.3.7. Poland
  9.3.8. Rest of Europe
9.4. Europe Active Pharmaceutical Ingredients Market - Opportunity Analysis Index, By Type of synthesis, Application, and Country, 2017 – 2023
9.5. Europe Active Pharmaceutical Ingredients Market Dynamics – Trends

10. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2. Type of Synthesis Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  10.2.1. Biotechnological
  10.2.2. Synthetic
  10.2.3. Semi-Synthetic
10.3. Application Area Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  10.3.1. Cardiovascular system
  10.3.2. Oncology
  10.3.3. CNS & Neurological system
  10.3.4. Orthopaedic
  10.3.5. Endocrinology
  10.3.6. Pulmonology
  10.3.7. Gastrointestinal system
  10.3.8. Nephrology system
  10.3.9. Ophthalmology
  10.3.10. Others
10.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
  10.4.1. Japan
  10.4.2. China
  10.4.3. India
  10.4.4. ASEAN
  10.4.5. Australia & New Zealand
  10.4.6. Rest of Asia-Pacific
10.5. Asia-Pacific Active Pharmaceutical Ingredients Market - Opportunity Analysis Index, By Type of synthesis, Application and Country, 2017 – 2023
10.6. Europe Active Pharmaceutical Ingredients Market Dynamics – Trends

11. LATIN AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

11.1. Type of Synthesis Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  11.1.1. Biotechnological
  11.1.2. Synthetic
  11.1.3. Semi-Synthetic
11.2. Application Area Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.2.1. Cardiovascular system
  11.2.2. Oncology
  11.2.3. CNS & Neurological system
  11.2.4. Orthopaedic
  11.2.5. Endocrinology
  11.2.6. Pulmonology
  11.2.7. Gastrointestinal system
  11.2.8. Nephrology system
  11.2.9. Ophthalmology
  11.2.10. Others
11.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.3.1. Brazil
  11.3.2. Mexico
  11.3.3. Argentina
  11.3.4. Venezuela
  11.3.5. Rest of Latin America
11.4. Latin America Active Pharmaceutical Ingredients Market - Opportunity Analysis Index, By Type of synthesis, Application, and Country, 2017 – 2023
11.5. Latin America Active Pharmaceutical Ingredients Market Dynamics – Trends

12. MIDDLE EAST AND AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

12.1. Type of Synthesis Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.1.1. Biotechnological
  12.1.2. Synthetic
  12.1.3. Semi-Synthetic
12.2. Application Area Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  12.2.1. Cardiovascular system
  12.2.2. Oncology
  12.2.3. CNS & Neurological system
  12.2.4. Orthopaedic
  12.2.5. Endocrinology
  12.2.6. Pulmonology
  12.2.7. Gastrointestinal system
  12.2.8. Nephrology system
  12.2.9. Ophthalmology
  12.2.10. Others
12.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.3.1. Gulf Cooperation Council (GCC) Countries
  12.3.2. Israel
  12.3.3. South Africa
  12.3.4. Rest of MEA
12.4. MEA Active Pharmaceutical Ingredients Market - Opportunity Analysis Index, By Type of synthesis, Application and Country, 2017 – 2023
12.5. MEA Active Pharmaceutical Ingredients Market Dynamics – Trends

13. COMPETITION LANDSCAPE

13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  13.2.1. Abbott Laboratories (U.S.)
  13.2.2. AstraZeneca plc (U.K.)
  13.2.3. Modified Polymer Components, Inc. (Bristol-Myers-Squibb) (U.S)
  13.2.4. Gilead Sciences (U.S.)
  13.2.5. GlaxoSmithKline Plc (U.K.)
  13.2.6. F. Hoffmann-La Roche AG (Switzerland)

14. RESEARCH METHODOLOGY

15. KEY ASSUMPTIONS AND ACRONYMS